about
Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.The changing burden of hepatitis C virus infection in the United States: model-based predictions.Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaCurrent and emerging antiviral treatments for hepatitis C infectionEfficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infectionDirect-acting antiviral agents in patients with hepatitis C cirrhosis.Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.Is stronger better in curing hepatitis C virus infection?Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.Quercetin: bioflavonoids as part of interferon-free hepatitis C therapy?
P2860
Q31170657-10B21450-AD58-498E-A9D4-AB9549AB0629Q33834742-DCE328CE-A36C-445A-B013-98BD993B872FQ35168083-0E0814E7-EB07-4202-9612-96ABA8DBA153Q35785198-A9A3F55D-29DF-4E88-A0B5-4624EEA99822Q36460249-16CA550D-AA78-4DEF-BF1F-49249455D27BQ36729900-C6C391DB-AEE5-4916-A306-6C912F3D451AQ37097611-04B9CC5E-1789-40FA-9C39-497F312D80D0Q37663921-4FFE8AAB-7B6D-438F-859B-8026080A3EA0Q37738808-0A5BE7E3-1971-4D8A-AF0B-B02BF1B20A48Q38111844-44615F26-F7B1-4C48-BB3B-EB03A3116372Q38398290-C6CD6F9E-8D49-4A68-89FB-50E8B72FCA1CQ40458975-8D27C711-A7C3-45F6-AB2A-43894ED908C5Q41923154-DD55BA85-1770-47EF-A59D-47BD944277D5Q42981703-AC94CFD9-5032-4A87-BF24-8CBFD97CC7E4
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Future treatment of patients with HCV cirrhosis.
@ast
Future treatment of patients with HCV cirrhosis.
@en
Future treatment of patients with HCV cirrhosis.
@nl
type
label
Future treatment of patients with HCV cirrhosis.
@ast
Future treatment of patients with HCV cirrhosis.
@en
Future treatment of patients with HCV cirrhosis.
@nl
prefLabel
Future treatment of patients with HCV cirrhosis.
@ast
Future treatment of patients with HCV cirrhosis.
@en
Future treatment of patients with HCV cirrhosis.
@nl
P2093
P2860
P1433
P1476
Future treatment of patients with HCV cirrhosis.
@en
P2093
Asma Khaloun
Claire Wartelle-Bladou
Isabelle Portal
Marc Bourlière
Paul Castellani
Souad Benali
Valérie Oules
Xavier Adhoute
P2860
P304
P356
10.1111/J.1478-3231.2011.02702.X
P478
32 Suppl 1
P577
2012-02-01T00:00:00Z